Ticagrelor is a medication that is used to prevent blood clots in people with acute coronary syndrome, a condition that can lead to heart attacks or strokes. It is sold under the brand name Brilinta and is classified as a platelet aggregation inhibitor.
The ticagrelor market has been steadily growing over the years due to the increasing incidence of acute coronary syndrome and the growing awareness about the benefits of antiplatelet drugs in preventing blood clots. The market growth can be attributed to several factors such as the increasing prevalence of cardiovascular diseases, growing geriatric population, and rising demand for personalized medicine. Additionally, the launch of new formulations, increasing R&D activities, and favourable reimbursement policies are also expected to drive the market growth in the coming years.
North America is currently the largest market for ticagrelor, followed by Europe and Asia-Pacific. The dominance of these regions can be attributed to the high prevalence of cardiovascular diseases, well-established healthcare infrastructure, and increasing awareness about the benefits of antiplatelet drugs.
To Get Details : https://analyticsmarketresearc....h.com/reports/ticagr